ANN ARBOR, Mich., March 02, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Canadian patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig. This patent further protects Kraig’s growing portfolio of spider silk Intellectual Property.

Patent number 2,812,791, titled “Chimeric Spider Silk and Uses Thereof” was issued to the University of Notre Dame (UND) under the Company’s exclusive license agreement. Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights. This patent provides protection for the Company’s proprietary recombinant spider silk through September of 2031.

“Congratulations to both the researchers at the University of Notre Dame and Kraig’s science team. Kraig Labs plans to continue building upon and protecting our position as a leading biomimicry company. This patent is an important step on the Company’s path to remaining the premier technology and fiber supplier in the spider silk space,” said Jon Rice, the Company’s Chief Operations Officer. “We’ve created multiple strains of high-performance spider silk fibers that we are excited about. Protecting our specialized materials in key end markets is a core component of our commercialization efforts.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company received its first small shipment of spider silk from Prodigy textiles, its wholly-owned Vietnamese subsidiary.

The Company has received fiber requests from a broad range of interested parties, including companies that produce products in the fields of sports apparel, industrial textiles, first responder supplies, medical products, and other manufacturers. In order to meet this demand, the Company established Prodigy Textiles to scale up the production of its recombinant spider silk fibers, threads, and textiles.

The Company’s operations at its Prodigy Textiles facility are now moving forward to significantly expand the Company’s spider silk production. The Company expects to begin filling the backlog of material requests, including requests from Polartec LLC and MtheMovement, as this added capacity comes online.

“I want to thank the Prodigy Textiles team for making this milestone possible and setting the stage for our expansion. This helps us transition from being the leading developer of spider silk technologies to the producer and supplier of high quality spider silk fibers,” said Jon Rice, the Company’s Chief Operations Officer. “Now we can focus on meeting the substantial demand for spider silk and solidifying market channel partnerships to reach our goal to develop and bring new products to market.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has filed a patent application protecting its most advanced knock-in knock-out gene editing technologies for the creation of nearly pure spider silk.

Entitled “Modification of Heavy Chain Fibrion in Bombyx Mori“, this patent covering the core technologies the Company has developed for the mass production of nearly pure spider silk fibers. Specifically, the Company has leveraged the application of knock-in knock-out technology to create the most genetically advanced and purest spider silk fibers in the Company’s history. The Company has also filed a corresponding patent application under the global Patent Cooperation Treaty process to protect these technologies internationally.

These technologies and inventions were first disclosed in a provisional patent filed with the United States Patent and Trademark Office (USPTO) under applications #62/995,717 on February 11, 2020. This full patent application, now filed, takes advantage of that earlier priority date in the USPTO’s first to file patent system. The Company made the discovery of this breakthrough public during a press conference held on April 16, 2020 where it reported the creation of this new technology with a spider silk purity nearly ten times greater than Dragon Silk, the Company’s previously developed recombinant spider silk fibers.

“Since first reporting the development of this new Knock-in, Knock-out gene-editing system, we have moved forward rapidly to bring this nearly pure spider silk to market. The filing of this full patent application is well-timed as we expect to begin transitioning this new, purer spider silk technology to our production facility in the near future,” said Kim Thompson, CEO and founder of Kraig Labs. “These technologies are core to the commercialization of spider silk, and we will continue to push forward aggressively to protect and grow intellectual property while we remain squarely focused on the commercialization and generating sales.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Jan. 26, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it is forming a joint venture partnership with MtheMovement, an eco-friendly luxury streetwear apparel line, part of the Kings Group of Companies and its affiliated companies (“Kings Group”).

The joint venture will develop and sell Kraig Labs’ spider silk fibers under the new innovative apparel and fashion brand, trade named SpydaSilk™ and potential other trademarks to be announced. All intellectual property related to SpydaSilk™ will be jointly owned by Kraig Labs and Kings Group. The deal combines Kraig Labs’ industry leading fibers with Kings Group’s business skills and regional enterprise expertise, creating what we believe will be a strong vertical integration for both companies.

Under the terms of this agreement, Kraig Labs granted the joint venture and the SpydaSilk brand an exclusive geographic license to all Kraig Lab technologies for the ASEAN region, in exchange for a 4 year firm commitment to purchase up to $32 million, with an additional projected purchase of $8 million, of Kraig Labs’ raw recombinant spider silk, with an initial payment of $250,000.

“SpydaSilk’s mission is to create high-impact products and technologies, so partnering with Kings Group, which we believe has strong product development expertise and intense understanding of ASEAN market, is a powerful combination that we believe will drive SpydaSilk’s sales and innovation,” said Kim Thompson, Kraig Labs’ founder and CEO. “Kraig Labs has always been proud to maintain our vanguard position in the spider silk space; this agreement strengthens our leadership role with a partner who shares our vision and places Kraig Labs and Kings Group on the best path for success. Spider silk is among the strongest fibers produced in nature, and the agreement represents the world’s first large-scale commitment to purchase spider silk fibers”

The new SpydaSilk alliance combines the strengths of both companies and calls on Kraig Labs to provide fibers and materials expertise, while Kings Group will lead the marketing, sales, and distribution. The two companies will work together to increase Kraig Labs’ product development agility and production scalability.

Under this collaboration, Kraig Labs and Kings Group believe that the material will not only be applied to apparel; the joint venture is also exploring uses to enhance other industries such as building construction and medical industries.

“Kings Group is dedicated to helping unleash the benefits of spider silk and this bold enterprise, the unveiling of the SpydaSilk^TM joint venture, significantly accelerates that goal. We believe that we will help improve the world through innovation to drive profitable growth, reduce emissions, enhance customer loyalty, and create long-term shareholder value,” said Mr. Walter Wee, Chief Investment Officer of Kings Group. “In researching various spider silk technologies, we came to the conclusion that Kraig Labs is the leader. Our agreement with Kraig Labs represents the first large-scale commitment to spider silk commercialization and we could not be happier to begin this part of our SpydaSilk™ journey.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and MtheMovement:

Kings Group is headquartered in Singapore and established regional offices in Indonesia and Vietnam. They have associate companies spread throughout Asia that have a dynamic synergy for maximizing resources and outreach to a huge consumer market. Kings Group is a forerunner in International Marketing and Innovative Product Trading; they specialize in bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg, www.kingsglobalconsultants.com

MtheMovement is Kings Group’s premiere eco-friendly luxury streetwear line, for the past 20 years, they have been the leaders of fashion trends and have consulted designs with branding for many renowned corporates. Their Chief Creative Officer has also dressed many of the Grammy and Emmy Awards participants and famous international fashion celebrities.

For more information, please visit www.mthemovement.com

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Dec. 11, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $950,000 in bridge financing and simultaneously filed with the SEC to become a mandatory, fully reporting company. Today the Company filed a Form 8-A to become fully reporting issuer. This financing will also make a significant contribution to that effort.

“While being a voluntary filer, Kraig has been committed to meeting all SEC filing and reporting standards. Our election to now formalize these reporting responsibilities is evidence of our commitment to full operational transparency and growth,” said CEO and Founder, Kim Thompson. “The bridge financing will be used to continue scaling up our recombinant spider silk production and for other purposes related to the near term implementation of our business plan.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Oct. 28, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has delivered its latest batch of spider silk silkworm eggs to its production facility in Vietnam.

This delivery marks the first shipment of the Company specialized recombinant spider silk silkworm eggs to Vietnam since the global outbreak of COVID-19. With restrictions on operations and travel in Vietnam now lifting, the Company is able to resume the scale up of spider silk production.

“With our silkworms now delivered, we are moving quickly, resuming production, and working to develop opportunities with apparel brands to bring exciting new products to market,” said CEO and Founder Kim Thompson. “We believe that this delivery puts us back on track with our plans for production and further commercialization opportunities.”

Operations at the Company’s production facility in Vietnam have now resumed and production scale up is underway.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Oct. 15, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has completed production and genetic screening of its latest batch of spider silk silkworm eggs. These specialized silkworm eggs are now ready for shipment to Vietnam to restart commercial production.

Production operations at the Company’s factory were suspended in March due to a mandatory shutdown, resulting from the global spread of COVID-19. During the COVID-19 quarantine, Kraig Labs’ U.S.-based team focused its efforts on improving the performance and genetics of its Dragon Silk strain of recombinant spider silk silkworms. Kraig Labs’ U.S. operations also used this time to scale up its supply of silkworm eggs to allow for a restart of its operations in Vietnam.

“Our teams have done a fantastic job, making significant progress in our genetics, production readiness, and R&D,” said CEO and Founder, Kim Thompson. “We believe that these silkworm eggs that are now ready for shipment to our factory, represent the future of spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., June 29, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has completed the development phase of a new program targeting the largest challenge facing global silk production, viral pathogens. As reported in the Journal of Biological Control, volume 31, viral diseases can result in total annual silk production losses of as much as 32%. 

Kraig Labs has developed its first immune-enhancing genetic insert, designed to create disease-resistant silkworms. The Company is now ready for its first round of transgenic creation and resistance testing. This effort was done in a parallel, and complementary, effort to the Company’s groundbreaking program developing high-performance spider silk inspired silk fibers and yarns.

Global silk production is expected to reach USD 17 billion in 2021; the economic impact of eliminating the loss from disease is a multi-billion dollar opportunity. The Company anticipates that its development of a disease resistant silkworm could be licensed across the entire global silk industry.

“Our work to enhance the disease resistance of our silkworms complements and strengths our focus in bringing our recombinant spider silk to market,” said CEO and Founder, Kim Thompson. “We believe that success in this effort will also provide significant opportunities for growth far beyond the reach of Kraig’s in-house production capacity, with licensing applications globally.”

Once proven, the Company expects to merge these disease resistance properties within its existing lines of genetically enhanced recombinant spider silks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., June 09, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has submitted its formal application to list the Company’s common stock on the Nasdaq Capital Market.

“After significantly strengthening our technology, business model, and corporate governance, to position Kraig Labs for future growth, an uplisting to the Nasdaq Capital Market is the natural evolution for the Company and our shareholders.  We are pleased to be working on the process with the Maxim Group for this raise of up to $24 million,” stated Kim Thompson, Kraig Biocraft Laboratories’ CEO and Chairman of the Board. “Kraig Labs has been blessed with loyal shareholders, and we expect that moving to Nasdaq will raise the Company’s visibility and expand our shareholder family.”

The Company’s application for uplisting, to the Nasdaq Capital Market, is subject to approval based on the ability to meet Nasdaq requirements. The Company intends to satisfy all of the applicable listing requirements, however, no assurance can be given that this application will be approved. During the Nasdaq review process, the Company’s common stock will continue to trade on the OTCQB under its current symbol, KBLB. 

Management believes that listing on the Nasdaq Capital Markets will expand opportunities for the Company’s recombinant spider silk materials within the technical textiles markets.  Analysts forecast that the global technical textile market was valued at nearly $235 billion in 2017, and is projected to reach about $335 billion by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

The Company has filed a registration statement with the Securities and Exchange Commission on Form S-1, which has not yet become effective, and plans to conduct an offering of its securities in order to raise sufficient funds to meet the Nasdaq requirements as well as fund its continued growth and operations. No securities may be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For a copy of the draft registration statement, please contact ir@kraiglabs.com or visit www.kraiglabs.com/sec-filings/. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., May 18, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”) announces that the Company’s Board of Directors held its first meeting with its four new members-elect in attendance.  During this meeting, management briefed the board on the Company’s plans for 2020 expansion and growth.  The scheduled increases in spider silk production for 2020 and the role of the new “knock-in/knock-out” technology were also discussed.

The Company’s expansion of its Board of Directors is intended to strengthen its corporate governance and to directly address the requirements for listing on a national exchange. 

The new members-elect are expected to be formally nominated and seated as voting members within the next sixty days. The expanded board brings a wealth of experience in international manufacturing operations, corporate finance, and accounting.  The board will help the Company navigate what management expects to be a period of significant growth.

“The Kraig Labs Board of Directors is being expanded, with three independent directors and with the appointment of Jon Rice, the Company’s COO, to satisfy the governance criteria for listing on a national exchange,” said Chairman and CEO, Kim Thompson.  This very positive upgrade in our corporate governance has been part of our growth plan since our last shareholder meeting, in 2019.  As the Company grows, so should the level of oversight.”

Thompson continued, “Our first meeting with the expanded board was very productive, including discussions of specific committee appointments.  The new members were selected for the unique strengths that each brings to our operations, as we work to significantly expand our production.  Our management team is looking forward to the formal appointment of these new members, in the very near future, and I want to thank each of them for their work and enthusiasm.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com